Loading…
← CockpitCompetitor Analysis › CRSP CRISPR Therapeutics AGOpen in the cockpit ↗

CRISPR Therapeutics AGCRSPCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Gene-editing biotech that co-developed Casgevy, the first approved CRISPR therapy, for sickle cell disease and beta-thalassemia.

Momentum weak 21
Mkt cap
$3.90B
US dollars, full cap
Free float
93%
of shares outstanding
$/day
$88.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 13.1%
Hurdle
n/a
no reverse DCF
Next earnings
90 days
16 Feb 2027
Close · USD$40.19
1D+0.1%
1W-12.2%
1M-19.4%
3M-30.9%
6M-17.2%
YTD-23.4%
1Y-27.4%
ATR %6.4%
Beta1.88
52w lowhigh36.7% off high

What CRISPR Therapeutics does

Gene-editing biotech that co-developed Casgevy, the first approved CRISPR therapy, for sickle cell disease and beta-thalassemia.

Does not sell Casgevy itself: Vertex runs commercialisation and the two split costs and profits, so CRISPR's income depends on how many patients complete the lengthy treatment process at authorised centres. Beyond that it funds research from its cash reserves, with in-house gene-editing programmes for heart disease and diabetes.

Products and services

  • Casgevy (sickle cell/beta-thalassemia, with Vertex)
  • Pipeline: in vivo gene editing (cardiovascular, diabetes)
  • CAR-T cell therapy pipeline

Customers

  • Hematologists treating sickle cell disease and tha
  • Pharma partner Vertex Pharmaceuticals

Where it sits in the supply chain

  • Healthcare
  • Biotechnology
  • CRISPR gene-editing drug discovery and…

What could go right

  • Casgevy commercial ramp across treatment centers globally
  • Pipeline expansion into broader diseases (in vivo editing)

What could go wrong

  • Casgevy's complex, costly one-time treatment logistics limit near-term uptake
  • Cash burn funding a broad pipeline

Moat: narrow (IP / patents, process know-how). A foundational CRISPR/Cas9 patent estate and being first to market with an approved gene-editing cure.

Headquarters: Zug, Switzerland · Founded: 2013

Named competitors

CRISPR Therapeutics at a glance

Size CRISPR Therapeutics (CRSP) is a United States Health Care company (Biotechnology) with a market value of $3.90B, the 1353rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $40.19 on 18 Nov 2026.

Performance Over six months the shares fell 17.2%, against +2.0% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue fell 34.3% over the last twelve months (peer median +6.3%); the operating margin is -2,058.6% (peer median -3.6%).

Valuation It trades at 95.6× enterprise value to sales against a peer median of 8.3× (4th most expensive of 16).

Short interest Short interest is 17.7% of the free float (30 Oct 2026).

Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 101CRSP 81
Six months, rebased to 100: CRISPR Therapeutics against the median of its 20 peers (local-currency closes).

CRISPR Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$25.2M$3.51M$37.3M$371M$1.20M
Revenue growth—-91%-90%+30,885%—
Gross profit-$174M-$229M-$92.2M$221M-$133M
EBITDA-$500M-$549M-$447M-$203M-$649M
Net income-$456M-$582M-$366M-$154M-$650M
Free cash flow-$377M-$346M-$145M-$270M-$533M
Capital expenditure$2.08M$914,000$1.90M$9.47M$37.2M
Total debt$780M$207M$224M$239M$244M

Quarterly statements and history in the cockpit →

CRISPR Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-20%-10%0%+10%6696TNGX6127RLAY603392ABCLIRON1530600161IOVA000661EWTX002252ELVNADPTDNTH0020073347VIRPCRSP6-month return →1-month return →
Up and to the right = strong over both horizons. CRISPR Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%0×2,000×4,000×6,000×6127RLAYABCL1530600161IOVA0006616919DNTH3347VIRPCRSPRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CRISPR Therapeutics is the large dot.

CRISPR Therapeutics competitors and peer comparison

Head to head with its named competitors (CRSP vs NTLA vs EDIT vs VRTX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
CRISPR Therapeutics CRSP$3.90B-17%-34%-2,059%95.6×n/a
Intellia Therapeutics NTLA$1.37B-20%-8%-821%21.3×n/a
Editas Medicine EDITn/a-32%n/an/an/an/a
Vertex Pharmaceuticals VRTX$136B+25%+11%35%10.5×6.2%

How CRISPR Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CRISPR Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureCRSPPeer medianRank in peer set
1-month return-19.4%-5.3%3rd lowest of 21
6-month return-17.2%+2.0%4th lowest of 21
Distance from 52-week high-36.7%-31.1%7th lowest of 21
Revenue growth (TTM)-34.3%+6.3%3rd lowest of 17
Operating margin-2,058.6%-3.6%4th lowest of 16
EV / Sales95.6×8.3×4th most expensive of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-2,059%95.6×n/an/a
Lin BioScience 6696.TWOTaiwan$3.98B+305%n/an/an/an/an/a
Tango Therapeutics TNGXUnited States$3.71B+4%-100%n/an/an/an/a
JOINN Laboratories (China) 6127.HKHong Kong$3.70B+6%+17%-4%12.4×n/an/a
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%273.1×n/an/a
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-35%12.7×n/an/a
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%43.4×n/an/a
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a
3SBio 1530.HKHong Kong$4.28B-31%+102%61%0.9×n/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%4.5×2.2%+12.5%
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%8.3×n/an/a
Changchun High-Tech Industry (Group) 000661.SZChina$4.52B-13%-18%-1%2.8×32.4%+7.1%
Edgewise Therapeutics EWTXUnited States$4.53B+26%n/an/an/an/an/a
Shanghai RAAS Blood Products 002252.SZChina$4.57B-15%-22%17%5.4×n/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%6,626.2×n/an/a
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Adaptive Biotechnologies ADPTUnited States$4.61B+104%+18%-16%15.8×n/an/a
Dianthus Therapeutics DNTHUnited States$4.73B-5%-12%-8,684%1,432.1×n/an/a
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%5.3×15.8%-1.8%
Hangzhou Tigermed Consulting 3347.HKHong Kong$4.75B0%+22%10%4.8×25.4%+15.6%
Virbac VIRP.PAFrance$3.20B-4%+4%15%2.1×5.8%+9.4%

Questions

Who are CRISPR Therapeutics's main competitors?
Named competitors: Intellia Therapeutics (NTLA), Editas Medicine (EDIT), Vertex Pharmaceuticals (partner) (VRTX). The cockpit's measured peer set (industry) also includes Lin BioScience (6696.TWO), Tango Therapeutics (TNGX), JOINN Laboratories (China) (6127.HK), Relay Therapeutics (RLAY), Beijing Wantai Biological Pharmacy Enterprise (603392.SS), AbCellera Biologics (ABCL).
Is CRISPR Therapeutics expensive compared with its peers?
On ev / sales it trades at 95.6× against a peer median of 8.3×, 4th most expensive of 16 in its peer set.
How has CRISPR Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -17.2% against +2.0% for the median peer; over one year -27.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.